🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

💡Did you know? CAMO members get a discount on Article Processing Charges (APC) when publishing in the open access journal Current Oncology! #MedOnc #OpenAccess #CAMOMembers Current Oncology Sharlene Gill, MD, MPH, MBA, FASCO Erin David Dawe CAMOPREZ

A plug for our Alliance for Clinical Trials in Oncology trial for patients with BRCA1/2 or PALB2 mutant pancreas cancer! #NCTN #PancChat Eileen M O’Reilly Kim Reiss Binder (Kim Reiss) Mike Pishvaian Efrat Dotan MD Hagen Kennecke Anirban Maitra Sharlene Gill, MD, MPH, MBA, FASCO PanCAN BasserBRCA @FacingOurRisk

Presented at #AACR25: Neoadjuvant PD-1 blockade with dostarlimab led to organ preservation in a high proportion of patients with early-stage mismatch repair–deficient tumors, with no compromise of surgical options. Full study results: nej.md/3EsWcoi  AACR

#CCTG2025 CCTG On my way home after a productive #GI #cancertrials annual meeting - busy weekend working to advance #trialsthatmatter for our patients 🎯 …also managed to fit in time for connection and camaraderie 🤗 Fortunate to be a part of this community 🇨🇦

#Bumrun 🏃🏻‍♀️ Was great to join Bumrun today with my colleagues to help raise funds for #colorectal #cancer education and awareness! Colorectal Cancer Resource & Action Network #BumrunToronto #CRCawareness #GetScreened

#CCTG2025 Advancing #cancer #clinicaltrial progress requires international collaborations 🌎 ➡️grateful for our CCTG GIDSC 🇨🇦 partnership with #AGITG GI Cancer Institute and AGITG 🇦🇺 🇳🇿 🙏🏻 Chris Flinders University for joining us!

👋Expanding Expertise Grant to Support Guest Speakers in Medical Oncology - Submission Deadline May 31, 2025. Designed to support and enhance medical oncology education through guest speaker events. Additional details, contact Canadian Association of Medical Oncologists. Sharlene Gill, MD, MPH, MBA, FASCO Erin David Dawe

#WorkoutBC #WhyIWorkout BC Cancer Foundation WorkoutBC 🏃‍♀️ This May, I will be moving every single day to raise funds for life-saving research and care BC Cancer I will move for the people who cannot and for every survivor who now feels strong. Together, we are stronger than cancer!

#ASCO25 ASCO 4 weeks away and looks like it is going to be a practice-changing #ASCO25 for #GIcancers👍 👇my top picks for key abstracts to watch for🌟 ➡️Two GI plenary sessions🏅 MATTERHORN #STCsm Yelena Y. Janjigian MD ATOMIC #dMMR #CRCsm Frank Sinicrope, MD ➡️Clinical Science Symposium

Happy #ClinicalTrialsDay everyone! We at #CCTG are honored to contribute to cancer research and improved treatments and outcomes. Thank you to all of the individuals who help make our research possible. #CancerResearch buff.ly/DOs9bnd

❔ ctDNA detection is PROGNOSTIC for inferior outcomes following resection of stage III colon cancer, but is treating more aggressively better? ‼️ NO improvement in RFS by escalating treatment with a ctDNA-informed approach. Congrats to DYNAMIC-III study team for highly

🚨DYNAMIC-III🚨 🔎R0 resected stage 3 colon cancer, post-op ctDNA + Randomized SoC vs intensified Systemic therapy ⛔️No improvement in RFS with intensification 🧐While ctDNA+ is prognostic, work is needed to identify how tx/selection may be altered to ⬆️outcomes #ASCO25

Original Article: Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer (BREAKWATER phase 3 trial) nej.md/3ScDaWC #ASCO25 | ASCO

#ASCO25 ASCO DESTINY Gastric04 Ph3 2L TDXd vs RAM/PTX in HER2+ GC/GEJ adeno N=494, 40% Asia, 80%. IHC 3+ ➡️ OS 14.7m v 11.4m (HR0.70, p=0.044)) ➡️ ORR 44 v 29% No new safety signals 🇨🇦 approved with +CDA ‼️CCTG open GA.4 trial w zanidatamab permits prior TdXD!

#ASCO25 ASCO CM577 adj nivo in resected yp+ esoph/GEJ after CRT 📌 SOC based on DFS ➡️ trend for OS - improved by 15mos - benefit in SCC, PDL1+ ➡️worse OS in PDL1- ⛔️ ✅Reaffirms benefit of adj nivo in PDL1+ ‼️PDL1 testing needed 🤔how will this cf ESOPEC & MATTERHORN

Excited to accept the role of Editor-in-Chief for Clinical Colorectal Cancer 🤗 #GIcancers #EiC #ClinicalColorectalCancer Elsevier